Should Evidation Health prioritize expanding its clinical trial recruitment capabilities or focus on enhancing its existing health tracking features?

Introduction

The trade-off question at hand is whether Evidation Health should prioritize expanding its clinical trial recruitment capabilities or focus on enhancing its existing health tracking features. This scenario involves balancing growth opportunities with core product improvement. I'll analyze this trade-off by examining the business context, user impact, technical considerations, and potential outcomes.

Step 1

Clarifying Questions (3 minutes)

• Business Context: I'm thinking Evidation's revenue model might be split between clinical trial recruitment and consumer subscriptions. Could you clarify the current revenue breakdown between these two streams?

Why it matters: Helps prioritize which area to focus on for immediate financial impact Expected answer: 60% from clinical trials, 40% from subscriptions Impact on approach: Higher clinical trial revenue would lean towards expanding recruitment capabilities

• User Impact: Based on user behavior, I'm assuming there's a subset of highly engaged users who might be ideal for clinical trials. What percentage of users actively use health tracking features daily?

Why it matters: Indicates potential for cross-selling clinical trial opportunities Expected answer: 30% of users are daily active users Impact on approach: High daily engagement would support enhancing health tracking features

• Technical Feasibility: Considering the complexity of clinical trial matching, I'm curious about our current technical capabilities. How sophisticated is our existing algorithm for matching users to clinical trials?

Why it matters: Determines the level of investment needed for expansion Expected answer: Basic matching based on demographic data Impact on approach: Less sophisticated matching would require more resources for expansion

• Resource Allocation: Given the potential scope of both options, I'm wondering about our current team structure. How are our engineering and product teams currently allocated between these two areas?

Why it matters: Indicates potential for quick wins or necessary restructuring Expected answer: 70% on health tracking, 30% on clinical trials Impact on approach: Uneven allocation might suggest focusing on the understaffed area

• Timeline Pressure: Considering market dynamics, I'm thinking there might be competitive pressure in the clinical trial space. Are there any immediate opportunities or threats in the clinical trial recruitment market we need to address?

Why it matters: Helps prioritize short-term vs. long-term focus Expected answer: A major pharma partner is looking to expand trials in the next quarter Impact on approach: Immediate opportunity would push towards prioritizing clinical trial capabilities